Rongchang Biopharmaceutical (Yantai) Co., Ltd. (hereinafter referred to as 'Rongchang Biotech') successfully listed on March 31, 2022, with an issued share number of 5,442.6301 million shares and an issue price of 48.00 yuan per share.
The company is an innovative biopharmaceutical enterprise with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. The company is committed to discovering, developing, and commercializing innovative, first-in-class, and best-in-class biologics that are characterized by their originality, aiming to create clinical value-oriented solutions for major diseases such as autoimmune diseases, oncology, and ophthalmic diseases, to meet a large number of unmet clinical needs. Relying on its core technology platform and strong R&D capabilities, the company has always been dedicated to developing targeted bio-innovative drugs with new structures and mechanisms. Products designed and developed through independent innovation have shown breakthrough therapeutic effects in clinical trials. The company owns the world's first, first-in-class B lymphocyte stimulator (BLyS)/proliferation-inducing ligand (APRIL) bispecific fusion protein product Rituximab (RC18), as well as China's first independently developed ADC innovation drug, currently the only Chinese ADC product granted breakthrough therapy designation by the US FDA (RC48). Frost & Sullivan has long been monitoring the global and Chinese biopharmaceutical industries, publishing a large number of research reports, which are widely cited in the prospectuses of leading science and technology innovation board listed companies in the industry, helping customers accelerate their growth.
Global Autoimmune Disease Medication Market Overview
It is expected that the global autoimmune disease treatment market will grow from $120.6 billion in 2020 to $146.1 billion by 2025, with a compound annual growth rate of 3.9%. By 2030, it will grow to $175.2 billion, accounting for more than 80% of the market, with the growth rate of biologics exceeding that of the overall market.
Global market size of drugs for autoimmune diseases2016 - 2030E
Source: Frost & Sullivan report
Overview of the Chinese Autoimmune Disease Drug Market
Based on China's vast population, the Chinese market has a large group of patients with autoimmune diseases. With the development and improvement of diagnostic technology for autoimmune diseases in our country, as well as economic development and the increase in people's income levels, the demand for medical services will be stimulated in the coming years. It is estimated that the overall market size will reach $8.7 billion by 2025, with a compound annual growth rate of 28.1% from 2020 to 2025, and maintaining a compound annual growth rate of over 20% after 2025, reaching a market size of $24.7 billion by 2030.
Market size of drugs for autoimmune diseases in China, 2016 - 2030E
Source: Frost & Sullivan report
Global & China
Systemic lupus erythematosusOverview of the Therapeutic Drug Market
The global market size for biologics for the treatment of systemic lupus erythematosus (SLE) is expected to increase from $900 million in 2020 to $52 billion in 2025, with a compound annual growth rate of 41.6% from 2020 to 2025, and is projected to grow at a compound annual rate of 22.1% to reach $143 billion by 2030. The continuous growth in the number of SLE patients in China and the continuous introduction of biologics will also drive rapid growth in the market size of SLE biologics in China. In 2020, the market for SLE treatment drugs in China reached $300 million, with a relatively small proportion of biologics. In the future, with the continuous introduction of SLE biologics products in China and the continuous improvement of the clinical penetration rate of biologics, the market for SLE biologics in China is expected to rapidly increase to $32 billion by 2030.
Global market size of drugs for systemic lupus erythematosus, 2016-2030E
Source: Frost & Sullivan report
Market scale of drugs for the treatment of systemic lupus erythematosus in China, 2016-2030E
Source: Frost & Sullivan report
Global & China Oncology Drug Market Overview
In recent years, factors such as the intensification of population aging have led to a high incidence trend of cancer globally. At the same time, advancements in biotechnology have rapidly developed tumor treatment methods, effectively improving the means of treating tumors and enhancing patient survival benefits, driving the rapid expansion of the tumor drug market. From 2016 to 2020, the global anti-tumor drug market size grew from $937 billion to $1503 billion, with a compound annual growth rate of 12.5%. It is estimated that by 2025, the market size will reach $3048 billion, with an annual compound annual growth rate of 15.2% from 2020 to 2025, and it is expected to further grow at a compound annual growth rate of 9.6% to reach $4825 billion by 2030.
Unlike the global pharmaceutical market landscape, the start of targeted therapy and immunotherapy in China's oncology drug market is relatively late, which has affected the development of the oncology drug market to some extent. In 2020, the market size of anti-tumor drugs in China reached 197.5 billion yuan. The progress in cancer treatment methods will lead to an upward trend in the Chinese anti-tumor drug market over the next few years. It is estimated that the Chinese anti-tumor drug market will reach 416.2 billion yuan by 2025, with a compound annual growth rate of 16.1% from 2020 to 2025. By 2030, the relevant market size is expected to reach 683.1 billion yuan. Currently, the Chinese anti-tumor drug market is dominated by chemotherapy drugs, accounting for 63.4% of the overall market. Given the promotion of favorable policies, the launch of new drugs, and the improvement in patients' affordability, the proportion of targeted therapy and immunotherapy in the market will significantly increase, leaving huge future market space for targeted therapy and immunotherapy drugs.
Market scale of anti-tumor drugs in China2016 - 2030E
Source: Frost & Sullivan report
Global Gastric Cancer Drug Market Overview
The continuous introduction of new anti-HER2 candidate drugs and the increasing number of gastric cancer patients are expected to drive sustained growth in the global and Chinese gastric cancer drug markets. The global gastric cancer drug market is projected to increase from $14.4 billion in 2020 to $242 billion by 2025, with a compound annual growth rate of 11.0% from 2020 to 2025, and reaching $364 billion by 2030. In 2020, the Chinese gastric cancer drug market size reached $4.3 billion and is expected to increase to $7.9 billion by 2025, with a compound annual growth rate of 12.8%. It is estimated that from 2025 to 2030, the Chinese market will grow at a compound annual rate of 10.2%, reaching a market size of $128 billion by 2030.
Global gastric cancer drug market, 2016 - 2030E
Source: Frost & Sullivan report
Overview of the Chinese Wet Age-related Macular Degeneration Market
From 2016 to 2020, the number of patients with wet age-related macular degeneration (AMD) in the United States increased from 1.7787 million to 1.8665 million, with an annual compound growth rate of 1.2%. In China, the number of patients with wet AMD increased from 3.2925 million in 2016 to 3.7627 million in 2020, with a compound annual growth rate of 3.4%. It is estimated that by 2025, the number will further increase to 4.3237 million, with a compound annual growth rate of 2.8% from 2020 to 2025.
Prevalence of age-related macular degeneration with wet AMD in China and the United States
2016 - 2030E
Source: Frost & Sullivan report
Frost & Sullivan, integrating 61 years of global consulting experience, has dedicated 24 years to serving the booming Chinese market. With a global perspective, we help clients accelerate their business growth, achieving industry-leading benchmarks in growth, innovation, and leadership. The healthcare industry is one of Frost & Sullivan's core areas of focus. Over the past seventeen years, the Frost & Sullivan healthcare team has provided financing financial advisory, IPO industry advisory, strategic consulting, management consulting, and other services to hundreds of outstanding domestic and international biopharmaceuticals, medical devices, healthcare services, and internet healthcare companies. Successful listings include: Ruike Biotech (2179.HK), Leop Bio (2157.HK), Clear Medical (1406.HK), Bexian An (2185.HK), Yonghe Medical (2279.HK), Kailaiying (6821.HK), Beihai Kangcheng (1228.HK), Gusheng Tang (2273.HK), Yingtong Technology (2251.HK), Clover Biotech (2197.HK), Minimally Invasive Robotics (2252.HK), Harmony Cayman (2256.HK), Kunbo Medical (2216.HK), Xianruida (6669.HK), Kangsheng Global (9960.HK), Yimaitong (2192.HK), Tengsheng Bopharm (2137.HK), Canopy (2162.HK), Chaoyu Ophthalmology (2219.HK), Guichuang Tongqiao (2190.HK), Hua Huang Medicine (0013.HK), Koi Pharmaceutical (2171.HK), Zhaoke Ophthalmology (6622.HK), Nature Pharmacy (UPC.NASDAQ), Sainfo Pharmaceutical (6600.HK), Zhaoyan New Drugs (6127.HK), Novogene Health (6606.HK), Tianyan Pharmaceutical (ADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao (2161.HK), Minimally Invasive Heart Link (2160.HK), Rui Li Medical Beauty (2135.HK), Jiake Pharmaceutical (1167.HK), HepB Pharma (2142.HK), JD Health (6618.HK), Deqi Pharma (6996.HK), Rongchang Biotech (9995.HK), WuXi AppTec (2126.HK), Sonovent Biologics (2096.HK), Yunding New Energy (1952.HK), Jiahe Biotech (6998.HK), Zai Ding Pharma (9688.HK), Ocular Biotech (1477.HK), Yongtai Biotech (6978.HK), Haipu Pharmaceutical (9989.HK), Kechuang Pharmaceutical (9939.HK), Peijia Medical (9996.HK), Kangfang Biotech (9926.HK), Nuo Cheng Jian Hua (9969.HK), Tianjing Biotech (IMAB.NASDAQ), Kanglong Chemical (3759.HK), China Antibody (3681.HK), Dongyao Pharmaceutical (1875.HK), Yasheng Medicine (6855.HK), Fuhong Hanlin (2696.HK), Hansoh Pharmaceutical (3692.HK), Mabtech Pharma (2181.HK), Fangda Holdings (1521.HK), Via Biotech (1873.HK), CStone Pharma (2616.HK), Junshi Biosciences (1877.HK), WuXi AppTec (2359.HK), Xinda Biotech (1801.HK), Hualing Medicine (2552.HK), BeiGene (6160.HK), Gilead Sciences (1672.HK), WuXi AppTec (2269.HK), China Resources Medicine (3320.HK), Jacobus Pharmaceutica (2633.HK), Hua Huang China Medicine (HCM.NASDAQ), Biotechnology (1548.HK), BBI Life Sciences (1035.HK), etc. In terms of the number of filings, the Frost & Sullivan healthcare team maintains an absolute leading position in Hong Kong's healthcare IPO market, consistently ranking first in market share from 2018 to 2021.
Since the listing of the first batch of companies on the Sci-tech Innovation Board in July 2019, Frost & Sullivan reports have been widely cited in the prospectuses of leading Sci-tech Innovation Board listed companies in the industry. These include: Rendu Biotech (688193.SH), Shouyao Holdings (688197.SH), Heyuan Biotech (688238.SH), Yaxin Security (688225.SH), Xidi Microelectronics (688173.SH), Mawei Biotech (688062.SH), Yahong Medicine (688176.SH), BeiGene (688235.SH), Jiahe Meikang (688246.SH), Dizhe Medicine (688192.SH), Novozyme (688105.SH), Chengda Biology (688739.SH), Geke Microelectronics (688728.SH), Huaxi Biosciences (688363.SH), Junshi Biosciences (688180.SH), Zhejiang Genomics (688266.SH), BeiGene (688177.SH), and Shenzhou Cells (688520.SH). They are considered the most powerful, professional, and influential industry research institutions in the sector. We hope to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's healthcare industry, and build a healthy future.
Recommended Reading
01. Frost & Sullivan assists Ruike Biotech in successfully listing on the Hong Kong Stock Exchange (2179.HK)
Frost & Sullivan helps Zhaoyan New Drugs successfully list on the Hong Kong Stock Exchange (6127.HK)
37. Frost & Sullivan assists WuXi AppTec Biologics (HKG 2126) on its successful listing in Hong Kong
41. Frost & Sullivan assists Zai Lab to successfully go public in Hong Kong (9688.HK)
49. Frost & Sullivan assisted Tianjing Biology in successfully going public in the US (IMAB.NASDAQ)
